Clinical Trials Browser

Camurati-Engelmann Syndrome, Inflammation, Arrhythmogenic Right Ventricular Dysplasia

NCT05637216 2026-04-24

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

Phase 2 Recruiting

43 enrolled

Breast

Radiation Fibrosis Syndrome, Breast Neoplasms, Camurati-Engelmann Syndrome, Fibrosis, Inflammation

NCT02065362 2026-01-29

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

Phase 1 Active not recruiting

14 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Camurati-Engelmann Syndrome

NCT05141539 2024-11-21

Rehabilitation Assessment and Progress Tracking System Based on Video Images for Dysphagic Patients

Phase NA Completed

30 enrolled

Head & Neck

Camurati-Engelmann Syndrome, Fibrosis, Head and Neck Neoplasms, Neoplasms, Radiation Injuries

NCT04297748 2023-01-17

Bioimaging Study of 89Zr-M7824 in NSCLC

Phase 1/2 Terminated

5 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Camurati-Engelmann Syndrome

NCT01620970 2021-05-14

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Phase 2 Completed

14 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Neoplasm Metastasis, Recurrence

NCT01401062 2019-03-05

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

Phase 2 Completed

23 enrolled 8 charts

Breast

Breast Neoplasms, Camurati-Engelmann Syndrome

NCT00889954 2018-09-18

HERCREEM

Phase 1 Completed

20 enrolled

Camurati-Engelmann Syndrome

NCT01402193 2014-06-25

Study of Arimidex and Radiotherapy Sequencing

Phase 3 Unknown

220 enrolled

Breast

Breast Neoplasms, Camurati-Engelmann Syndrome

Clinical Trials

LI-ARVC

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

Rehabilitation Assessment and Progress Tracking System Based on Video Images for Dysphagic Patients

Bioimaging Study of 89Zr-M7824 in NSCLC

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

HERCREEM

Study of Arimidex and Radiotherapy Sequencing